The "Acute Pancreatitis Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Acute Pancreatitis - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Pancreatitis pipeline landscape is provided which includes the disease overview and Acute Pancreatitis treatment guidelines.
The assessment part of the report embraces, in depth Acute Pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Acute Pancreatitis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Acute Pancreatitis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Acute Pancreatitis pipeline report covers 10+ companies. Some of the key players include CalciMedica (CM 4620), Samsung Bioepis (SB 26), GlaxoSmithKline (GSK 3335065) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Acute Pancreatitis Analytical Perspective
In-depth Acute Pancreatitis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Acute Pancreatitis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Key Topics Covered:
1. Report Introduction
2. Acute Pancreatitis
2.1. Acute Pancreatitis Disease Overview
2.2. Acute Pancreatitis History
2.3. Acute Pancreatitis Symptoms
2.4. Acute Pancreatitis Causes
2.5. Acute Pancreatitis Pathophysiology
2.6. Acute Pancreatitis Diagnosis
3. Acute Pancreatitis Current Treatment Patterns
3.1. Treatment Guidelines
4. Acute Pancreatitis- Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acute Pancreatitis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Acute Pancreatitis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Acute Pancreatitis Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.4. Assessment by Molecule Type
4.2.5. Assessment by MOA
5. Acute Pancreatitis Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.3. Early Stage Products (Phase-I)
5.4. Pre-clinical and Discovery Stage Products
5.5. Inactive Products
6. Acute Pancreatitis-Products Analysis
6.1. Product Profiles
6.1.1. CM 4620: CalciMedica
6.1.2. SB 26: Samsung Bioepis
6.1.3. GSK 3335065: GlaxoSmithKline
7. Recent Technologies
8. Acute Pancreatitis Key Companies
8.1. CalciMedica
8.2. Vernalis
8.3. Eisai Co Ltd
8.4. Cytopathfinder
8.5. Samsung Bioepis
8.6. Sun BioPharma
8.7. ICOS Corporation
8.8. ChiRhoClin
8.9. Amersham
8.10. GlaxoSmithKline
9. Acute Pancreatitis Key Products
9.1. CM 4620
9.2. SB 26
9.3. GSK 3335065
9.4. CM 128
9.5. Lexipafant
9.6. Patamostat mesylate
9.7. PG 103
9.8. SBP 101
9.9. PAF-acetylhydrolase
9.10. Secretin
9.11. IT 9302
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Acute Pancreatitis - Unmet Needs
12. Acute Pancreatitis - Future Perspectives
13. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pclioy
View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005878/en/
Contacts:
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
